Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2019

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism

Johann Foloppe, et al. Molecular Therapy Oncolytics, March 2019 – Download the article Publication

Published 27 March 2019
Categorized as -others, 2019, Publication, TG6002

Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

20190326 PR BioInvent extension CDR US

Published 26 March 2019
Categorized as 2019, Invir.IO, Press release

Transgene: A positive 2018, moving ahead with a strong portfolio

20180320 FY RESULTS EN

Published 20 March 2019
Categorized as 2019, Press release

Transgene secures a €20 Million Revolving Credit Facility with Natixis

20190318 PR Natixis loan EN

Published 18 March 2019
Categorized as 2019, Press release

NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme

20190313 – Neoviva – EN

Published 13 March 2019
Categorized as 2019, Press release

Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC

20190305-PR-NEC-Agreement-US-1

Published 5 March 2019
Categorized as 2019, Myvac, Press release, TG4050

Posts pagination

Newer posts Page 1 … Page 4
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu